Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bivalent COVID-19 mRNA Vaccine (LVRNA021) in China
NCT05547256Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of LVRNA021 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoints: Incidence of solicited adverse events at 28 days, Incidence of unsolicited adverse events at 28 days and 1 more. Status: unknown.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05547256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547256.